Globin gene therapy for treating hemoglobinopathies

A globulin and gene technology, applied in hemoglobin/myoglobin, gene therapy, blood diseases, etc., can solve problems such as being unfavorable for producing high titer vectors and effectively transducing HSC in patients

Active Publication Date: 2017-09-26
MEMORIAL SLOAN KETTERING CANCER CENT +1
View PDF30 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, the use of large LCR segments may be detrimental to the generation of high-titer vectors and efficient transduction of patient HSCs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Globin gene therapy for treating hemoglobinopathies
  • Globin gene therapy for treating hemoglobinopathies
  • Globin gene therapy for treating hemoglobinopathies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0261] Example 1: Discovery of new insulators

[0262] The problems created by insertional mutagenesis of viral vectors are well known (Nienhuis (2013), Baum et al. (2006), Nienhuis et al. (2006)), as the risk of genotoxicity can be reduced by using chromatin insulators (Arumugam et al. (2007), Emery (2011), Evans-Galea et al. (2007), Rivella et al. (2000), Emery et al. (2000), Emery et al. (2002), Yannaki et al. (2002), Hino et al. ( 2004), Ramezani et al. (2003), Ramezani et al. (2008)). Methods have been developed that allow the efficient identification of enhancer-blocking insulators in the human genome. These new insulators are short, averaging 150 bp, and they do not adversely affect the titer of viral vectors, and they are several times more potent than the insulator cHS4. Using a genomic approach to discover the most powerful enhancer blockers and barrier insulators of the human genome. For gene therapy in hemoglobinopathies, strong enhancers are required to achie...

Embodiment 2

[0267] Example 2: Characterization of globulin carriers comprising at least one insulator

[0268] Production of the expression cassette disclosed in the present invention (referred to as "expression cassette 1", such as figure 1 shown), which contains insulator A1, and human β encoding a threonine-to-glutamine mutation at codon 87 A -globin gene (β A-T87Q ), operably linked to the β-globin LCR region, the β-globin LCR region comprises the HS2 region having the nucleotide sequence shown in SEQ ID NO:9, the nucleotide sequence having the nucleotide sequence shown in SEQ ID NO:5 The HS3 region and the HS4 region having the nucleotide sequence shown in SEQ ID NO:7. Using the variant beta chain (beta A ) rationale is to facilitate the detection of vector-encoded β-globin genes, distinguishing them from endogenous or imported β-chains. A glutamine (GLN) residue at position 87 in the γ-globulin chain enhances the antisickling activity of the γ chain relative to the β chain whi...

Embodiment 3

[0270] Example 3: Evaluation of enhancer activity in non-erythroid K562 cells

[0271] Enhancer activity of HS2 was evaluated in nonerythroid K562 cells. Such as Figure 7 GFP expression in K562 cells transduced with the vector is driven by a minimal promoter linked to no enhancer ("blank", HS2, HS3-HS4, HS2-HS3-HS4, or the runx1 enhancer used as a positive control), as shown ("RUNX1"). Background expression was on the order of 0.01% ("Blank"), but increased more than 10-fold with HS2-HS3-HS4 ("Lcr9", 0.17%). This enhancement was mainly due to HS2 (0.15%), Instead of HS3-HS4 (0.05%). All cell lines were transduced equally (average vector copy number 2.5). Results support that HS2 but not HS3-HS4 may cause oncogenic risk in non-erythroid hematopoietic stem and progenitor cells.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The presently disclosed subject matter provides for expression cassettes that allow for expression of a globin gene or a functional portion thereof, vectors comprising thereof, and cells transduced with such expression cassettes and vectors. The presently disclosed subject matter further provides methods for treating a hemoglobinopathy in a subject comprising administering an effective amount of such transduced cells to the subject.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to US Provisional Application No. 62 / 045,997, filed September 4, 2014, the entire contents of which are incorporated herein by reference. [0003] Funding information [0004] This invention was made with government support under grant number HL053750 from the National Heart, Lung and Blood Institute. The government has certain rights in this invention. technical field [0005] The presently disclosed subject matter provides expression cassettes expressing globin proteins, such as human β-globin, and vectors comprising such expression cassettes. The presently disclosed subject matter also provides expression cassettes comprising a globin gene or functional portion thereof operably linked to a β-globin locus control region (LCR) comprising multiple DNase I hypersensitive sites. The expression cassettes of the presently disclosed subject matter comprise one or more insulators that counte...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/113C12N15/11
CPCC07K14/805C12N9/22C12N15/86C12N2740/15043C12N2830/40C12N2740/16043C12N2830/15C12N2830/48C12N2830/50A61K48/0058C12N15/85C12N2830/008C12N2830/30C12N2830/46A61K48/0066A61P7/06C12N15/113C12N2740/10043
Inventor M·塞德莱恩I·里维埃J·曼西利亚索托X·王G·斯塔马托扬诺普洛斯J·斯塔马托扬诺普洛斯M·刘
Owner MEMORIAL SLOAN KETTERING CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap